Phase III testing for nasal migraine drug

    Phase III testing has begun for a nasal treatment for migraine headaches.

    OptiNose Inc. of Yardley is moving forward with its bi-direction intranasal technology, the Philadelphia Business Journal reports.
    In short, the user exhales into a device that delivers the drug particles through one nasal passage, into the affected area and back out the other nasal passage.

    If things go accordingly, it might not be long before the company seeks FDA approval for the drug.

    • WHYY thanks our sponsors — become a WHYY sponsor

    WHYY is your source for fact-based, in-depth journalism and information. As a nonprofit organization, we rely on financial support from readers like you. Please give today.

    Want a digest of WHYY’s programs, events & stories? Sign up for our weekly newsletter.

    Together we can reach 100% of WHYY’s fiscal year goal